Prof. Chris Constantinou has a formal education in biomedical engineering at Stanford University, USA and was fortunate to be appointed to the clinical Department of Urology, Stanford Medical School for all of his professional life. Prof. Constantinou looks forward to developing links with groups interested in imaging technology particularly using ultrasound to address basic and clinical problems quantitatively.

1. Pharmacologic methods in identifying alpha adrenergic receptors in the obstructed urinary tract
2. Fluid mechanics and physiological mechanisms of contractility in the urinary tract
3. Biomedical Engineering approaches in the characterization of static and dynamic properties of soft tissues
4. Image processing and 3D reconstruction of magnetic resonance
5. Computer models and vector analysis of pelvic floor musculature
6. Software for interactive teaching

Jennifer Davagian-Ensign is the Founder and CEO of Christcot Medical Company. As a Crohn’s patient she knows the daily struggles of IBD patients and compliance decisions affecting healthcare outcomes. Ms Davagian-Ensign has given several talks including patient responsibility in compliance and the importance of new medical device technologies that motivate behavioral changes on the part of the patient. As a thought leader in the area of rectal medication treatment for gastrointestinal disease, Ms. Davagian-Ensign led the initiative to have Ulcerative Proctitis categorized as a Rare Genetic Orphan Disease by the NIH and wrote the abstract included in the NIH database.

Dr. Carol Ann Podlasek has received her Ph.D. in Biochemistry in University of Notre Dame during the period of 1987-1994. Currently, she is working as Assistant Professor in Northwestern University. She is serving as an editorial member of several reputed journals like Asian Journal of Andrology, ISRN Urology. She has authored 24 research articles/books. She is a member of American Urological Association.

Erectile dysfunction (ED) is a significant medical condition and current treatment options are ineffective in diabetic patients and in prostate cancer patients treated by prostatectomy. Sonic hedgehog (SHH) is an essential regulator of penile smooth muscle, cavernous nerve (CN) integrity and CN regeneration that has significant potential to be developed as a treatment to prevent ED by regenerating the CN and by suppressing penile apoptosis. In our laboratory we examine fundamental mechanisms that underlie cavernous nerve regulation of penile morphology during development, how these mechanisms become altered with peripheral neuropathy of the cavernous nerve in diabetic rats and how manipulation of SHH signaling can be used to speed cavernous nerve repair in CN injury models.

Min Li got his Ph.D. from Emory University at Atlanta, Georgia in 2002, under the supervision of Dr. Richard W. Compans, a world renowned virologist and immunologist. Li studied the regulation of a retrovirus envelope protein induced membrane fusion and the association with lipid rafts. He then moved on to Baylor College of Medicine at Houston, Texas, USA and started his career in cancer research as an Assistant Professor in 2004. Li joined the University of Texas Health Science Center at Houston, Medical School in 2010 as the Director of Cancer Research Program. His research interests include pancreatic cancer and brain tumor pathogenesis, translational research, new therapies and tumor vaccine development. Li′s group is the first one to identify a zinc transporter (ZIP4) as a new molecular target in pancreatic cancer, and has developed a novel therapy to treat this malignancy.

Pancreatic cancer and brain tumor pathogenesis. Translational research, new therapies (shRNA therapy, small molecule therapy, and nutrition/diet therapy), and tumor vaccine development.

Jerzy Jankun is the founding Director of Urology Research Center and Professor at Department of Urology, at Health Science Campus of University of Toledo, USA. His scientific research interest concentrates on Proteolysis in different cancers and other diseases. Inhibition of photolytic activity reduce cancer induced angiogenesis and consequently tumor growth. Additionally inhibitors of proteolysis can reduce cancer spread. Special interest includes modified proteins to be used in therapy. That includes Plasminogen Activator Type 1 with Very Long Half-Life (VLHL PAI-1) and modified human lipoxygenase. In the past laboratory, he explored photodynamic therapy to eradicate prostate and other cancers using small molecular weight photosensitizers and sensitizers conjugated with antibodies in targeted Photodynamic Cancer Therapy (PDT).

Dr. Jerzy Jankun’s research interest concentrates on Proteolysis in different cancers and other diseases. Inhibition of photolytic activity reduce cancer induced angiogenesis and consequently tumor growth.he explored photodynamic therapy to eradicate prostate and other cancers using small molecular weight photosensitizers and sensitizers conjugated with antibodies in targeted Photodynamic Cancer Therapy (PDT).

Dinesh Vyas, MD, is an Assistant Professor in the Department of Surgery. Dr. Vyas is trained in surgery from Rajasthan University, and subsequently trained at Washington University School of Medicine, University of Pittsburgh, Case Western Reserve University and Birmingham University, UK. He has been to various institutes of excellence in France as well. Dr. Vyas is on the editorial board of various clinical and basic science journals including Human Genetics and Embryology, Journal of Laparoendoscopic and Advanced Surgical Technique, Gastroenterology and Hepatology (Canada), Journal of Gastroenterology and Hepatology Research, World Journal of Gastroenterology, Reference.Medscape.com, Newsletter, Arogyaa.com.

Dr. Vyas’ research interests and projects include nanotechnology, application of novel nanomolecules in breast cancer, especially triple negative breast cancer and study its role in minorities and under privileged classes of society, study the role of these therapies to reduce sepsis from chemotherapy, abdominal sepsis, quality of life after liver resection, apoptosis, parapoptosis, cytokines in sepsis and oncology, and cost analysis in cancer patients.

Paraskevi Theofilou has received her PhD at Panteion University during the period of 2010. Currently, she is working as a research fellow at Panteion University. She has successfully completed her Administrative responsibilities as Head of Personnel Department at General Hospital. She is serving as an editorial member of several reputed journals like Frontiers in Psychology for Clinical Settings, Europe. Journal of Psychology, International Journal of Biomedicine, World Journal of Urology

Psychosocial processes, outcomes and quality of life in chronic illness with particular emphasis on chronic kidney disease, dialysis and renal transplantation Self management interventions for patients with chronic illness, Palliative care in severe chronic disease.